Engineering the Medicines of Tomorrow
MorphoSys has established HuCAL as a leading technology for the development of fully human antibodies. The Company uses its proprietary technology in two areas: for the development of novel therapeutics as well as research and diagnostic antibodies.
In the therapeutic segment, MorphoSys has created a strong market position and validated its technology through several corporate partnerships. The Company is currently involved in more than 50 different partnered therapeutic development programs in addition to a rapidly growing number of internal programs targeting inflammation and cancer. Proprietary drug development offers very significant potential for the Company. MorphoSys is committed to exploiting this potential and building the Company’s value.
All currently marketed antibody therapeutics are based on the research results of the past years and decades. Scientists worldwide are now working on the medicines of the future. Through its involvement in the research antibody market, MorphoSys is securing its access to innovative therapeutic approaches and opening up new opportunities, for example, in disease diagnosis.